Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	40.5	36.86	26.58	0.04	0.83
Revenue Growth (YoY)	9.88%	38.65%	61716.28%	-94.81%	-98.03%
Cost of Revenue	73.02	148.27	173.39	132.01	67.04
Gross Profit	-32.52	-111.41	-146.8	-131.97	-66.21
Selling, General & Admin	40.81	59.54	56.96	36.89	21.9
Operating Expenses	40.81	59.54	56.96	36.89	21.9
Operating Income	-73.34	-170.96	-203.77	-168.86	-88.11
Interest Expense	-3.87	-4.07	-3.33	-1.27	-0.36
Interest & Investment Income	8.44	12.07	2.88	0.07	0.42
EBT Excluding Unusual Items	-68.77	-162.96	-204.21	-170.06	-88.05
Merger & Restructuring Charges	-	-8.71	-	-	-
Pretax Income	-68.77	-171.67	-204.21	-170.06	-88.05
Income Tax Expense	0.42	-	-	-	-
Net Income	-69.19	-171.67	-204.21	-170.06	-88.05
Net Income to Common	-69.19	-171.67	-204.21	-170.06	-88.05
Shares Outstanding (Basic)	123	116	94	71	61
Shares Outstanding (Diluted)	123	116	94	71	61
Shares Change (YoY)	5.54%	23.98%	32.69%	14.79%	41.37%
EPS (Basic)	-0.56	-1.48	-2.18	-2.41	-1.43
EPS (Diluted)	-0.56	-1.48	-2.18	-2.41	-1.43
Free Cash Flow	-82.47	-171.05	-51.56	-140.64	-75.17
Free Cash Flow Per Share	-0.67	-1.47	-0.55	-1.99	-1.22
Gross Margin	-80.31%	-	-	-	-
Operating Margin	-181.09%	-463.86%	-766.59%	-392693.02%	-10641.30%
Profit Margin	-170.86%	-465.80%	-768.26%	-395488.37%	-10633.45%
Free Cash Flow Margin	-203.65%	-464.12%	-193.97%	-327060.47%	-9078.38%
EBITDA	-71.71	-169.44	-202.84	-168	-87.1
EBITDA Margin	-177.07%	-	-	-	-
D&A For EBITDA	1.63	1.52	0.93	0.86	1.01
EBIT	-73.34	-170.96	-203.77	-168.86	-88.11
EBIT Margin	-181.09%	-	-	-	-

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q